Skip to content
Open access

Pharmacokinetic and dosimetric evaluation of [177Lu]Lu-FAPI for stromal-targeted radionuclide therapy in triple-negative breast cancer: a preclinical biodistribution and dosimetry study

Nov 2026 · Frontiers in Oncology · 0 citations · 23 references

Abstract

Triple-negative breast cancer (TNBC) has limited targeted treatment options and is strongly influenced by stromal biology. This study evaluated [ 177 Lu]Lu-FAPI for fibroblast activation protein-alpha (FAP)-directed tumor microenvironment targeting in TNBC models. [ 177 Lu]Lu-FAPI was assessed using TNBC stromal FAP analysis, radiochemical quality control, in vitro stability, cellular uptake and blocking assays, internalization and retention studies, serial biodistribution, Single-photon emission computed tomography/computed tomography (SPECT/CT), autoradiography, Medical Internal Radiation Dose (MIRD)-based dosimetry, and preliminary systemic and histologic safety evaluation. The DOTA-FAPI-04 precursor (FAPI-4; CAS 2374782-02-0; molecular formula C 40 H 54 F 2 N 10 O 10 ; molecular weight, 872.92 g/mol) was obtained from a commercial supplier (MedChemExpress, Shanghai, China, Cat. No. HY-130196) with confirmed purity ≥95% via high-performance liquid chromatography (HPLC). TNBC stroma showed prominent FAP expression with α-SMA co-localization. [ 177 Lu]Lu-FAPI showed radiochemical purity of 98.7% ± 0.8% via radio-HPLC and 96.1% ± 1.2% via radio-thin-layer chromatography (radio-TLC). At 72 h, intact tracer remained at 92.1% ± 2.7% in saline and 83.4% ± 2.9% in serum. Competitive binding assays revealed an IC 50 of 12.3 ± 2.1 nM and a K i of 8.7 ± 1.5 nM for FAP. FAP-positive cancer-associated fibroblast (CAF)-like cells showed blocking-sensitive uptake, progressive internalization, and prolonged retention. Tumor uptake persisted through 72 h, while blood activity declined to 0.02%ID/g. SPECT/CT and autoradiography confirmed FAP-associated tumor localization. Revised dosimetry estimated absorbed dose as 0.73 ± 0.15 mGy/MBq for tumor and 4.83 ± 0.52 mGy/MBq for the kidney. The tumor-to-kidney absorbed-dose ratio was 0.15, confirming the kidney as the primary organ-at-risk consideration. [ 177 Lu]Lu-FAPI showed stromal-targeted TNBC localization and feasible preclinical dosimetry, with the kidney remaining the main organ-at-risk consideration. These findings establish the pharmacokinetic and dosimetric foundation for [ 177 Lu]Lu-FAPI in TNBC; however, therapeutic efficacy remains to be demonstrated in future studies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.